Login to Your Account



Staff Cut by 35 percent

Anemic ESA Market Dooms Neose Development Program

By Donna Young


Thursday, January 31, 2008
Based on poor prospects for profits and increased safety concerns of anemia drugs in general, Neose Technologies Inc. is discontinuing development of its erythropoiesis-stimulating agent (ESA), NE-180 (GlycoPEGylated erythropoietin). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription